Pieris Pharmaceuticals, Inc. (PIRS)
USD 13.6
(-15.58%)
USD 13.6
(-15.58%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 72.56 Million USD | -49.73% |
| 2022 | 61.2 Million USD | -23.08% |
| 2021 | 79.56 Million USD | 25.8% |
| 2020 | 63.24 Million USD | -13.88% |
| 2019 | 73.43 Million USD | 22.53% |
| 2018 | 59.93 Million USD | 50.32% |
| 2017 | 39.86 Million USD | 39.45% |
| 2016 | 28.58 Million USD | 72.09% |
| 2015 | 16.61 Million USD | 32.23% |
| 2014 | 12.56 Million USD | 34.71% |
| 2013 | 9.32 Million USD | -31.05% |
| 2012 | 13.52 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.17 Million USD | -22.45% |
| 2024 Q1 | 5.38 Million USD | -20.57% |
| 2023 Q4 | 6.78 Million USD | -58.74% |
| 2023 Q2 | 16.4 Million USD | 6.41% |
| 2023 Q1 | 15.41 Million USD | 10.34% |
| 2023 Q3 | 16.43 Million USD | 0.16% |
| 2023 FY | 56.87 Million USD | -7.07% |
| 2022 Q4 | 13.97 Million USD | -13.04% |
| 2022 Q2 | 14.84 Million USD | -9.02% |
| 2022 FY | 61.2 Million USD | -23.08% |
| 2022 Q1 | 16.31 Million USD | -11.08% |
| 2022 Q3 | 16.07 Million USD | 8.26% |
| 2021 Q1 | 20.69 Million USD | 44.82% |
| 2021 Q4 | 18.34 Million USD | -13.76% |
| 2021 Q3 | 21.27 Million USD | 10.52% |
| 2021 Q2 | 19.25 Million USD | -6.97% |
| 2021 FY | 79.56 Million USD | 25.8% |
| 2020 Q1 | 17.11 Million USD | -7.97% |
| 2020 Q2 | 15.9 Million USD | -7.1% |
| 2020 Q3 | 15.93 Million USD | 0.23% |
| 2020 FY | 63.24 Million USD | -13.88% |
| 2020 Q4 | 14.28 Million USD | -10.35% |
| 2019 Q2 | 17.56 Million USD | -8.66% |
| 2019 FY | 73.43 Million USD | 22.53% |
| 2019 Q4 | 18.6 Million USD | 3.07% |
| 2019 Q3 | 18.04 Million USD | 2.76% |
| 2019 Q1 | 19.22 Million USD | 9.49% |
| 2018 Q3 | 16.14 Million USD | 15.9% |
| 2018 FY | 59.93 Million USD | 50.32% |
| 2018 Q2 | 13.93 Million USD | 13.4% |
| 2018 Q1 | 12.28 Million USD | 5.35% |
| 2018 Q4 | 17.56 Million USD | 8.75% |
| 2017 FY | 39.86 Million USD | 39.45% |
| 2017 Q2 | 9.74 Million USD | 4.23% |
| 2017 Q3 | 9.11 Million USD | -6.49% |
| 2017 Q4 | 11.66 Million USD | 28.02% |
| 2017 Q1 | 9.34 Million USD | 2.38% |
| 2016 Q2 | 6.86 Million USD | 22.05% |
| 2016 FY | 28.58 Million USD | 72.09% |
| 2016 Q4 | 9.13 Million USD | 31.14% |
| 2016 Q3 | 6.96 Million USD | 1.38% |
| 2016 Q1 | 5.62 Million USD | 19.61% |
| 2015 Q2 | 3.53 Million USD | -4.49% |
| 2015 FY | 16.61 Million USD | 32.23% |
| 2015 Q3 | 4.29 Million USD | 21.5% |
| 2015 Q4 | 4.7 Million USD | 9.56% |
| 2015 Q1 | 3.7 Million USD | -28.69% |
| 2014 Q4 | 5.19 Million USD | 37189.84% |
| 2014 Q3 | 13.91 Thousand USD | 124.19% |
| 2014 Q2 | 6208.00 USD | 302.07% |
| 2014 Q1 | 1544.00 USD | -29.75% |
| 2014 FY | 12.56 Million USD | 34.71% |
| 2013 Q3 | 5762.00 USD | 0.0% |
| 2013 FY | 9.32 Million USD | -31.05% |
| 2013 Q4 | 2198.00 USD | -61.85% |
| 2012 FY | 13.52 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 73.635% |
| Alkermes plc | 996.24 Million USD | 92.716% |
| Agenus Inc. | 78.18 Million USD | 7.184% |
| Aptorum Group Limited | 10.56 Thousand USD | -686687.81% |
| Ardelyx, Inc. | 169.93 Million USD | 57.298% |
| Dyadic International, Inc. | 9.15 Million USD | -692.837% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -226.095% |
| Lantern Pharma Inc. | 17.87 Million USD | -305.905% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -977.935% |
| Novavax, Inc. | 779.12 Million USD | 90.686% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 10.481% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 11.716% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -273.695% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -145.106% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -36.591% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 80.929% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -198.544% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -91.624% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -135.826% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 14.342% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -315.684% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 56.918% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -121.813% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 54.586% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 95.969% |
| AlloVir, Inc. | 180.93 Million USD | 59.893% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 83.72% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -144.478% |
| Bicycle Therapeutics plc | 216.92 Million USD | 66.547% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 57.786% |
| ChromaDex Corporation | 56.37 Million USD | -28.711% |
| Chimerix, Inc. | 93.38 Million USD | 22.297% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -421.696% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 51.795% |
| CRISPR Therapeutics AG | 463.49 Million USD | 84.344% |
| Precision BioSciences, Inc. | 92.46 Million USD | 21.519% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 71.436% |
| Fortress Biotech, Inc. | 200.19 Million USD | 63.752% |
| Fortress Biotech, Inc. | 200.19 Million USD | 63.752% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -121.603% |
| ImmuCell Corporation | 9.61 Million USD | -654.531% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 54.018% |
| Immix Biopharma, Inc. | 16.14 Million USD | -349.572% |
| Incyte Corporation | 1.19 Billion USD | 93.905% |
| Innoviva, Inc. | 132.15 Million USD | 45.09% |
| IO Biotech, Inc. | 91.44 Million USD | 20.643% |
| Jaguar Health, Inc. | 42.01 Million USD | -72.715% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 57.132% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 13.943% |
| ContextLogic Inc. | 387 Million USD | 81.249% |
| MiMedx Group, Inc. | 229.72 Million USD | 68.412% |
| MEI Pharma, Inc. | 34.78 Million USD | -108.613% |
| NextCure, Inc. | 67.63 Million USD | -7.287% |
| Onconetix, Inc. | 34.9 Million USD | -107.881% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -469.324% |
| Opthea Limited | 191.96 Million USD | 62.199% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -2537.244% |
| Vaxcyte, Inc. | 468.04 Million USD | 84.496% |
| PDS Biotechnology Corporation | 43.04 Million USD | -68.581% |
| Precigen, Inc. | 84.18 Million USD | 13.798% |
| Pharming Group N.V. | 225.49 Million USD | 67.819% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 56.761% |
| PureTech Health plc | 144.59 Million USD | 49.815% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 44.293% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 70.4% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -198.544% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 68.267% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -135.153% |
| Acelyrin, Inc. | 422.06 Million USD | 82.807% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -562688.894% |
| Summit Therapeutics Inc. | 87.68 Million USD | 17.243% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -95.786% |
| Senti Biosciences, Inc. | 94.7 Million USD | 23.377% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 41.267% |
| Elevation Oncology, Inc. | 45.44 Million USD | -59.679% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -146.245% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -1740.82% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 45.099% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -112.897% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -758.668% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 59.975% |
| Seer, Inc. | 110.49 Million USD | 34.323% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -2.793% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 22.371% |
| ESSA Pharma Inc. | 32.13 Million USD | -125.822% |
| GlycoMimetics, Inc. | 39.28 Million USD | -84.715% |
| GT Biopharma, Inc. | 13.57 Million USD | -434.517% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 66.99% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 63.918% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 72.028% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -27.849% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -34.183% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -630.213% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 82.019% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -283.359% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -43.148% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 72.053% |
| Aptose Biosciences Inc. | 52.35 Million USD | -38.601% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -403.568% |
| Soligenix, Inc. | 7.79 Million USD | -830.9% |
| Century Therapeutics, Inc. | 56.07 Million USD | -29.418% |
| Kura Oncology, Inc. | 165.8 Million USD | 56.234% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 36.627% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -772.292% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -2824.116% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 32.621% |
| Autolus Therapeutics plc | 196.72 Million USD | 63.113% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 14.282% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 37.686% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -274.38% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 77.447% |
| GRI Bio, Inc. | 11.33 Million USD | -540.477% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -928.473% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 44.688% |
| IGM Biosciences, Inc. | 265.59 Million USD | 72.678% |
| INmune Bio, Inc. | 29.89 Million USD | -142.728% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 57.946% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -80.001% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -354.123% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -360.984% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -16.857% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 32.511% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 73.679% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 75.928% |
| Verastem, Inc. | 92.08 Million USD | 21.196% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -304.515% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 60.928% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 40.229% |
| Histogen Inc. | 14.27 Million USD | -408.45% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -352.177% |
| Surrozen, Inc. | 18.55 Million USD | -291.191% |
| Organovo Holdings, Inc. | 14.91 Million USD | -386.53% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -1325.592% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -21.606% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -182.941% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -54.376% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -850.707% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 59.264% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -49.781% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 70.382% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -372.233% |
| Apollomics, Inc. | 54.14 Million USD | -34.034% |
| Amarin Corporation plc | 272.35 Million USD | 73.356% |
| Mesoblast Limited | 5.9 Million USD | -1129.515% |
| Turnstone Biologics Corp. | 78.33 Million USD | 7.368% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 70.275% |
| Synaptogenix, Inc. | 8.31 Million USD | -772.832% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -397.504% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 71.324% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -117.719% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -721.697% |
| Exelixis, Inc. | 1.58 Billion USD | 95.427% |
| Better Therapeutics, Inc. | 38.26 Million USD | -89.656% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 68.728% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 91.515% |
| NLS Pharmaceutics AG | 11.8 Million USD | -514.598% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -802.348% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -141.943% |
| Gritstone bio, Inc. | 148.37 Million USD | 51.093% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -5.38% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -343.552% |
| Avid Bioservices, Inc. | 25.99 Million USD | -179.143% |
| Insmed Incorporated | 949.26 Million USD | 92.356% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -362.505% |
| MediWound Ltd. | 18.86 Million USD | -284.598% |
| OmniAb, Inc. | 83.89 Million USD | 13.504% |
| Alector, Inc. | 248.8 Million USD | 70.834% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 69.03% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -38.88% |
| Zai Lab Limited | 547.47 Million USD | 86.745% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 81.797% |
| Aura Biosciences, Inc. | 84.99 Million USD | 14.619% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 70.637% |
| Immunic, Inc. | 99.22 Million USD | 26.866% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 54.364% |
| Veracyte, Inc. | 357.93 Million USD | 79.726% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.195% |
| FibroGen, Inc. | 398.11 Million USD | 81.773% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -410.669% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -953.521% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -918.366% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 97.771% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -180.47% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 77.075% |
| TG Therapeutics, Inc. | 198.47 Million USD | 63.438% |
| Galecto, Inc. | 35.62 Million USD | -103.683% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -78.343% |
| Fortrea Holdings Inc. | 457.3 Million USD | 84.132% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -33.693% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -151.285% |
| XBiotech Inc. | 37.51 Million USD | -93.458% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -5.38% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -251.426% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 48.919% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 26.756% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 34.458% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 92.427% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -151.572% |
| Vaxxinity, Inc. | 56.05 Million USD | -29.464% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 83.149% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -225.287% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 34.547% |
| NexImmune, Inc. | 28.16 Million USD | -157.623% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -1211.999% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -305.566% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 97.422% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -185.031% |
| Scopus BioPharma Inc. | 11.71 Million USD | -519.435% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 42.889% |
| Ainos, Inc. | 12.95 Million USD | -460.24% |
| Pluri Inc. | 22.48 Million USD | -222.802% |
| Prothena Corporation plc | 282.4 Million USD | 74.304% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 63.721% |
| Celularity Inc. | 215.05 Million USD | 66.257% |
| Rallybio Corporation | 78.93 Million USD | 8.065% |
| Cue Biopharma, Inc. | 19.54 Million USD | -271.334% |
| MeiraGTx Holdings plc | 151.07 Million USD | 51.968% |
| Omeros Corporation | 94.75 Million USD | 23.414% |
| Humacyte, Inc. | 23.49 Million USD | -208.831% |
| Immunocore Holdings plc | 308.04 Million USD | 76.443% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -2040.59% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 16.461% |
| Blueprint Medicines Corporation | 722.86 Million USD | 89.961% |
| CalciMedica, Inc. | 21.81 Million USD | -232.612% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 2.805% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 54.799% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 57.637% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 75.396% |
| Pulmatrix, Inc. | 22.03 Million USD | -229.277% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -109.88% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 18.342% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 86.844% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -0.021% |
| Cytokinetics, Incorporated | 173.61 Million USD | 58.202% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -110.831% |
| Nutriband Inc. | 5.73 Million USD | -1165.532% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -66.386% |
| Vor Biopharma Inc. | 126.03 Million USD | 42.424% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 93.898% |
| Evogene Ltd. | 27.79 Million USD | -161.123% |
| ProKidney Corp. | 151.52 Million USD | 52.109% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 2.169% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -843.366% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 88.186% |
| CorMedix Inc. | 48.95 Million USD | -48.222% |
| BioLineRx Ltd. | 50.8 Million USD | -42.841% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 51.847% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -90.602% |
| Atai Life Sciences N.V. | 125.78 Million USD | 42.309% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 11.114% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 10.862% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 71.267% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -121.643% |
| MediciNova, Inc. | 10.9 Million USD | -565.727% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 43.669% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -899.597% |
| GeoVax Labs, Inc. | 6.02 Million USD | -1104.98% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 84.767% |
| Biomea Fusion, Inc. | 126.13 Million USD | 42.47% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 94.468% |
| Mereo BioPharma Group plc | 35.84 Million USD | -102.461% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 62.025% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 68.443% |
| Absci Corporation | 73.66 Million USD | 1.493% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -163.092% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 45.68% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 70.034% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 72.308% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 65.111% |
| Allakos Inc. | 196.05 Million USD | 62.987% |
| Imunon, Inc. | 20.31 Million USD | -257.284% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 36.048% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 80.314% |
| BioAtla, Inc. | 129.68 Million USD | 44.045% |
| NLS Pharmaceutics AG | 11.8 Million USD | -514.598% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -358.032% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 14.546% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -73.777% |
| XOMA Corporation | 46.46 Million USD | -56.18% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 34.726% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 49.063% |
| aTyr Pharma, Inc. | 12.97 Million USD | -459.103% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 29.993% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 58.023% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 71.516% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -93.985% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -782.281% |
| Akari Therapeutics, Plc | 16.8 Million USD | -331.786% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -3091.159% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 75.756% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -978.45% |
| UroGen Pharma Ltd. | 138.88 Million USD | 47.752% |
| Sutro Biopharma, Inc. | 243 Million USD | 70.139% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -897.523% |
| Orgenesis Inc. | 45.75 Million USD | -58.59% |
| Entera Bio Ltd. | 8.86 Million USD | -719.029% |
| GH Research PLC | 41.22 Million USD | -76.037% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -182.27% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 12.627% |
| Xencor, Inc. | 306.97 Million USD | 76.361% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -1370.851% |
| Replimune Group, Inc. | 234.77 Million USD | 69.091% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -254.155% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 62.165% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -978.45% |
| Portage Biotech Inc. | 18.19 Million USD | -298.736% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -899.597% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 30.864% |
| OncoCyte Corporation | 25.63 Million USD | -183.052% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -1090.464% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -533.374% |
| Purple Biotech Ltd. | -22.46 Million USD | 422.989% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -340.328% |
| scPharmaceuticals Inc. | 65.17 Million USD | -11.335% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -758.491% |
| HilleVax, Inc. | 133.34 Million USD | 45.58% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -605.552% |
| Tharimmune, Inc. | 9.45 Million USD | -667.47% |
| Genprex, Inc. | 31.06 Million USD | -133.627% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 61.303% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -131.271% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -9385.752% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -1232.239% |
| OKYO Pharma Limited | 8243.57 USD | -880173.959% |
| Savara Inc. | 15.74 Million USD | -360.883% |
| Curis, Inc. | 58.35 Million USD | -24.353% |
| Daré Bioscience, Inc. | 33.6 Million USD | -115.91% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -1324.962% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -872.604% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -168.544% |
| BeiGene, Ltd. | 3.28 Billion USD | 97.792% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -263.935% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 85.451% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 52.772% |
| Erasca, Inc. | 141.52 Million USD | 48.726% |
| bluebird bio, Inc. | 240.23 Million USD | 69.793% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -1502.969% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 95.845% |
| DBV Technologies S.A. | 92.16 Million USD | 21.261% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -1502.969% |
| Moderna, Inc. | 6.39 Billion USD | 98.865% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -70.307% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -405.123% |
| Molecular Templates, Inc. | 63.09 Million USD | -15.018% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -8.793% |
| Travere Therapeutics, Inc. | 472 Million USD | 84.626% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 49.365% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -16.887% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -67.149% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 65.134% |
| MacroGenics, Inc. | 217.21 Million USD | 66.593% |
| RenovoRx, Inc. | 11.39 Million USD | -536.767% |
| Adicet Bio, Inc. | 152.03 Million USD | 52.271% |
| Prime Medicine, Inc. | 186.63 Million USD | 61.12% |
| Aditxt, Inc. | 25.95 Million USD | -179.63% |
| Adagene Inc. | 41.83 Million USD | -73.473% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -892.682% |
| Quantum-Si incorporated | 111.65 Million USD | 35.011% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 57.774% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -397.785% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -102.574% |
| SciSparc Ltd. | 9.01 Million USD | -705.305% |
| Vericel Corporation | 142.04 Million USD | 48.912% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -738.267% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -214.294% |
| Generation Bio Co. | 144.46 Million USD | 49.77% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 12.603% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 16.07% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 75.461% |
| Invivyd, Inc. | 205.75 Million USD | 64.732% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -0.564% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -673.748% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 3.572% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -605.415% |
| 2seventy bio, Inc. | 289.88 Million USD | 74.967% |
| ADMA Biologics, Inc. | 66.58 Million USD | -8.981% |
| Clene Inc. | 41.07 Million USD | -76.676% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -466.573% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -32.429% |
| GeoVax Labs, Inc. | 6.02 Million USD | -1104.98% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 79.387% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -97.555% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -115.151% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 30.024% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -122.67% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 57.384% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 90.548% |
| Evaxion Biotech A/S | 22.27 Million USD | -225.846% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 46.463% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 69.105% |
| Trevena, Inc. | 38.41 Million USD | -88.91% |
| Surrozen, Inc. | 18.55 Million USD | -291.191% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 9.23% |
| Cingulate Inc. | 22.75 Million USD | -218.843% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 1068.58% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -62.46% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -781.303% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 29.244% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 90.377% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -16.902% |
| Clearmind Medicine Inc. | 8.74 Million USD | -730.146% |
| Kronos Bio, Inc. | 128.11 Million USD | 43.36% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 13.686% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -2374.135% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 28.029% |
| Statera Biopharma, Inc. | 28.82 Million USD | -151.707% |
| ImmunityBio, Inc. | 362.87 Million USD | 80.002% |
| Korro Bio, Inc. | 84.53 Million USD | 14.158% |
| Kineta, Inc. | 21.15 Million USD | -243.004% |
| BioVie Inc. | 31.95 Million USD | -127.122% |
| Codexis, Inc. | 66.51 Million USD | -9.092% |
| Celularity Inc. | 215.05 Million USD | 66.257% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 67.979% |
| Celcuity Inc. | 66.23 Million USD | -9.566% |
| Virax Biolabs Group Limited | 6.54 Million USD | -1008.375% |
| Cibus, Inc. | 320.3 Million USD | 77.345% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -68.758% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -114.413% |
| IN8bio, Inc. | 30.33 Million USD | -139.2% |
| Kodiak Sciences Inc. | 277.32 Million USD | 73.833% |
| Annexon, Inc. | 143.72 Million USD | 49.51% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 43.126% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -216.758% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -11238.438% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 90.692% |
| Eyenovia, Inc. | 25.4 Million USD | -185.62% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 48.284% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -1204.675% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 8.299% |
| Arcellx, Inc. | 200.19 Million USD | 63.753% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -58.096% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 66.468% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -628.794% |
| Moolec Science SA | 52.75 Million USD | -37.564% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -18.692% |
| Geron Corporation | 70.44 Million USD | -3.017% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -55.922% |
| Royalty Pharma plc | 862.4 Million USD | 91.586% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 22.861% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -677.949% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -220.684% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 65.081% |
| Humacyte, Inc. | 23.49 Million USD | -208.831% |
| Structure Therapeutics Inc. | 102.77 Million USD | 29.393% |
| 89bio, Inc. | 151.2 Million USD | 52.008% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 9.442% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -399.078% |
| Genelux Corporation | 24.33 Million USD | -198.196% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -113.914% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 58.023% |
| Notable Labs, Ltd. | 14.77 Million USD | -391.307% |
| Liquidia Corporation | 87.98 Million USD | 17.524% |
| Mustang Bio, Inc. | 48.5 Million USD | -49.618% |
| Immunovant, Inc. | 282.7 Million USD | 74.332% |
| Quantum-Si incorporated | 111.65 Million USD | 35.011% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -221.886% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -241.214% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 28.865% |
| Acasti Pharma Inc. | 11.3 Million USD | -542.12% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -216.59% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -354.123% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -55.915% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -6295.847% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -356.792% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -148.88% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -75.348% |
| PepGen Inc. | 84.76 Million USD | 14.393% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -144.899% |
| United Therapeutics Corporation | 885.1 Million USD | 91.801% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -216.924% |
| Solid Biosciences Inc. | 104.31 Million USD | 30.436% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -121.741% |
| Immuneering Corporation | 58.41 Million USD | -24.229% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -1325.592% |
| Silo Pharma, Inc. | 3.92 Million USD | -1750.297% |
| Belite Bio, Inc | 31.66 Million USD | -129.146% |
| XOMA Corporation | 46.46 Million USD | -56.18% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -7.426% |
| Bionomics Limited | 17.89 Billion USD | 99.594% |
| Apogee Therapeutics, Inc. | 93 Million USD | 21.975% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 303.38% |
| uniQure N.V. | 285.08 Million USD | 74.546% |
| Cassava Sciences, Inc. | 105.95 Million USD | 31.514% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -892.682% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 62.635% |
| Forte Biosciences, Inc. | 32.47 Million USD | -123.438% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -773.368% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -146.865% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -1204.675% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -410.669% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -716.357% |
| Altimmune, Inc. | 30.55 Million USD | -137.485% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 83.031% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 303.38% |
| Compugen Ltd. | 43.97 Million USD | -65.031% |
| Peak Bio, Inc. | 1249.13 USD | -5809223.289% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 2.097% |
| Benitec Biopharma Inc. | 22.38 Million USD | -224.216% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 70.161% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -154.234% |
| Zura Bio Limited | 62.63 Million USD | -15.85% |
| PolyPid Ltd. | 21.04 Million USD | -244.813% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -345.847% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -154.234% |
| Instil Bio, Inc. | 85.78 Million USD | 15.409% |
| argenx SE | 1.53 Billion USD | 95.268% |
| Immunome, Inc. | 122.82 Million USD | 40.917% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -49.704% |
| Verona Pharma plc | 67.15 Million USD | -8.063% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -180.34% |
| Shattuck Labs, Inc. | 93.61 Million USD | 22.484% |
| CervoMed Inc. | 14.95 Million USD | -385.139% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -2.635% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -749.321% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -42.286% |
| Moolec Science SA | 52.75 Million USD | -37.564% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -341.173% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 45.256% |
| AnaptysBio, Inc. | 181.56 Million USD | 60.034% |
| Design Therapeutics, Inc. | 78.19 Million USD | 7.193% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 16.63% |
| NeurAxis, Inc. | 8.82 Million USD | -722.632% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -476.607% |
| Lumos Pharma, Inc. | 38.66 Million USD | -87.679% |
| Achilles Therapeutics plc | 75.25 Million USD | 3.573% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -180.34% |
| 180 Life Sciences Corp. | 13.47 Million USD | -438.423% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -173.809% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -2374.135% |
| Nutriband Inc. | 5.73 Million USD | -1165.532% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 34.495% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -30.39% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -42.625% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -9.784% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -34.076% |
| Palisade Bio, Inc. | 13.32 Million USD | -444.79% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -59.805% |
| Beam Therapeutics Inc. | 554.19 Million USD | 86.906% |
| Neurogene Inc. | 55.58 Million USD | -30.554% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 70.797% |
| AEON Biopharma, Inc. | 48.42 Million USD | -49.84% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 24.965% |
| Sesen Bio, Inc. | 78.38 Million USD | 7.419% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 13.125% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -476.52% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 83.91% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 17.435% |
| Athira Pharma, Inc. | 125.46 Million USD | 42.163% |
| Vaccinex, Inc. | 23.45 Million USD | -209.384% |
| HCW Biologics Inc. | 21.02 Million USD | -245.1% |
| XOMA Corporation | 46.46 Million USD | -56.18% |
| Nektar Therapeutics | 190.9 Million USD | 61.988% |
| Arvinas, Inc. | 480 Million USD | 84.882% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -3091.159% |
| Merus N.V. | 200.49 Million USD | 63.806% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 29.79% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -109.607% |
| Rezolute, Inc. | 70.38 Million USD | -3.096% |
| Clene Inc. | 41.07 Million USD | -76.676% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -343.057% |
| BeyondSpring Inc. | 24.86 Million USD | -191.84% |
| Synlogic, Inc. | 58.53 Million USD | -23.977% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -305.578% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -1515.45% |
| Peak Bio, Inc. | 1249.13 USD | -5809223.289% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -20.051% |
| Krystal Biotech, Inc. | 160.42 Million USD | 54.767% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 73.186% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 79.15% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -3264.624% |
| MannKind Corporation | 125.59 Million USD | 42.223% |
| Ikena Oncology, Inc. | 84.57 Million USD | 14.201% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -652.213% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 19.012% |
| Gossamer Bio, Inc. | 183.75 Million USD | 60.51% |
| CohBar, Inc. | 12.38 Million USD | -485.763% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -43.06% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -163.092% |
| Legend Biotech Corporation | 583.14 Million USD | 87.556% |
| Mural Oncology plc | 192.07 Million USD | 62.219% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -8.07% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -349.457% |
| Disc Medicine, Inc. | 91.12 Million USD | 20.367% |
| Champions Oncology, Inc. | 28.11 Million USD | -158.15% |
| REGENXBIO Inc. | 321.15 Million USD | 77.405% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -1253.532% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -30.149% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -86.255% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 36.544% |
| Vaxart, Inc. | 90.72 Million USD | 20.016% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -751.713% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -69.57% |
| Cellectis S.A. | 97.32 Million USD | 25.436% |
| Longeveron Inc. | 21.25 Million USD | -241.487% |
| Repare Therapeutics Inc. | 167.35 Million USD | 56.64% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 94.667% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 4.07% |
| Revolution Medicines, Inc. | 498.76 Million USD | 85.451% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -990.89% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -65.095% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 2.714% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -4.209% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -556.112% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 98.48% |
| Denali Therapeutics Inc. | 527.23 Million USD | 86.236% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -738.267% |
| Veru Inc. | 101.34 Million USD | 28.399% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -210.018% |
| Cingulate Inc. | 22.75 Million USD | -218.843% |
| Passage Bio, Inc. | 108.38 Million USD | 33.05% |
| Context Therapeutics Inc. | 25.07 Million USD | -189.423% |
| Exicure, Inc. | 14.07 Million USD | -415.53% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 64.785% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -67.585% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -690.713% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 71.259% |
| Nuvalent, Inc. | 149.49 Million USD | 51.458% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -799.552% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 29.989% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -238.319% |
| OmniAb, Inc. | 83.89 Million USD | 13.504% |
| Anew Medical, Inc. | 1.3 Million USD | -5478.391% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -121.481% |
| Lipocine Inc. | 15.08 Million USD | -381.202% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -5.916% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 4.709% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -80.001% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 36.813% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -224.187% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 89.074% |
| Ocugen, Inc. | 71.56 Million USD | -1.396% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 22.692% |
| Q32 Bio Inc. | 92.68 Million USD | 21.703% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -242.713% |
| Alumis Inc. Common Stock | 158.17 Million USD | 54.123% |
| Equillium, Inc. | 50.6 Million USD | -43.394% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -16.28% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -421.849% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -284.657% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -54.557% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 33.098% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -485.553% |
| Dominari Holdings Inc. | 23.83 Million USD | -204.451% |
| Edesa Biotech, Inc. | 9.22 Million USD | -686.815% |
| vTv Therapeutics Inc. | 11.9 Million USD | -509.44% |
| Bio-Techne Corporation | 563.03 Million USD | 87.112% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 82.249% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 72.999% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 45.141% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -403.546% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 55.67% |
| Nkarta, Inc. | 131.65 Million USD | 44.88% |
| BioCardia, Inc. | 12.12 Million USD | -498.68% |
| Iterum Therapeutics plc | 47.46 Million USD | -52.874% |